These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25396266)

  • 1. Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults.
    Erlandson KM; Jiang Y; Debanne SM; McComsey GA
    AIDS; 2015 Jan; 29(2):175-82. PubMed ID: 25396266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy.
    Eckard AR; Jiang Y; Debanne SM; Funderburg NT; McComsey GA
    J Infect Dis; 2014 Apr; 209(8):1156-64. PubMed ID: 24415784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial.
    Ridker PM; MacFadyen JG; Wolfert RL; Koenig W
    Clin Chem; 2012 May; 58(5):877-86. PubMed ID: 22419750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.
    Ridker PM; Pradhan A; MacFadyen JG; Libby P; Glynn RJ
    Lancet; 2012 Aug; 380(9841):565-71. PubMed ID: 22883507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial.
    Dirajlal-Fargo S; Kinley B; Jiang Y; Longenecker CT; Hileman CO; Debanne S; McComsey GA
    AIDS; 2015 Jan; 29(3):313-21. PubMed ID: 25686680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial.
    Longenecker CT; Hileman CO; Funderburg NT; McComsey GA
    Clin Infect Dis; 2014 Oct; 59(8):1148-56. PubMed ID: 25015912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
    Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
    JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance.
    Kennedy SP; Barnas GP; Schmidt MJ; Glisczinski MS; Paniagua AC
    J Clin Lipidol; 2011; 5(4):308-15. PubMed ID: 21784377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy.
    Funderburg NT; Jiang Y; Debanne SM; Storer N; Labbato D; Clagett B; Robinson J; Lederman MM; McComsey GA
    Clin Infect Dis; 2014 Feb; 58(4):588-95. PubMed ID: 24253250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 96 Weeks of Rosuvastatin on Bone, Muscle, and Fat in HIV-Infected Adults on Effective Antiretroviral Therapy.
    Erlandson KM; Jiang Y; Debanne SM; McComsey GA
    AIDS Res Hum Retroviruses; 2016 Apr; 32(4):311-6. PubMed ID: 26477698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rosuvastatin for the treatment of dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Preliminary experience].
    Bottaro EG; Caravello O; Scapellato PG; Stambulian M; Vidal GI; Loggia V; Scapellato JL; Thompson F; Cassetti I
    Enferm Infecc Microbiol Clin; 2008; 26(6):325-9. PubMed ID: 18588813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.
    Ridker PM; MacFadyen JG; Glynn RJ; Chasman DI
    Circ Cardiovasc Genet; 2011 Jun; 4(3):312-7. PubMed ID: 21493817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
    Nissen SE; Nicholls SJ; Sipahi I; Libby P; Raichlen JS; Ballantyne CM; Davignon J; Erbel R; Fruchart JC; Tardif JC; Schoenhagen P; Crowe T; Cain V; Wolski K; Goormastic M; Tuzcu EM;
    JAMA; 2006 Apr; 295(13):1556-65. PubMed ID: 16533939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals.
    Kamat SA; Gandhi SK; Davidson M
    Curr Med Res Opin; 2007 May; 23(5):1121-30. PubMed ID: 17519079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of two intensive statin regimens on progression of coronary disease.
    Nicholls SJ; Ballantyne CM; Barter PJ; Chapman MJ; Erbel RM; Libby P; Raichlen JS; Uno K; Borgman M; Wolski K; Nissen SE
    N Engl J Med; 2011 Dec; 365(22):2078-87. PubMed ID: 22085316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
    Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, double-dummy, randomized, placebo-controlled trial to evaluate the effect of statin therapy on triglyceride levels in Mexican hypertriglyceridemic patients.
    Talavera JO; Martinez G; Cervantes JL; Marin JA; Rodriguez-Briones I; Gonzalez JG; Ocampo R; Sanchez-Mijangos H; Bernal-Rosales LP; Polanco A
    Curr Med Res Opin; 2013 Apr; 29(4):379-86. PubMed ID: 23323877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.